Answers are grounded in this paper and cite their sources.
Review outlines the therapeutic and biomarker potential of vascular endothelial growth factor in heart disease, highlighting translational challenges.
Cardiovascular diseases remain the leading cause of death worldwide, with ischemic heart disease (IHD) as the most common. Ischemia-induced angiogenesis is a process in which vascular endothelial growth factor (VEGF) plays a crucial role. To conduct research in the field of VEGF’s association in cardiovascular diseases, it is vital to understand its role in the physiological and pathological processes in the heart. VEGF-based therapies have demonstrated a promising role in preclinical studies. However, their potential in human therapies is currently under discussion. Furthermore, VEGF is considered a potential biomarker for collateral circulation assessment and heart failure (HF) mortality. Additionally, as VEGF is involved in angiogenesis, there is a need to elucidate the impact of VEGF-targeted therapies in terms of cardiovascular side effects.
No takes yet. Share an insight, caveat, or question.
Florek et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: